They estimated that 70% of Sovaldi sales were for Olysio/Sovaldi combinations.
Most surprising fact in the report/call. Raises many questions:
1) Will the huge cost caused by this treatment give GILD cover/reason to price all-oral higher than overwise?
2) Does this mean that docs will not use a 8 week treatment even if it approved to make sure that cure will happen?
3) Will all of the sickest people already have been treated and therefore the "warehousing" be much less than assumed and '15 estimates are too high for both GILD and ABBV?
4) Will ABBV view the current usage and cost as evidence that the market is willing to pay big dollars andthat the 8 week treatment will be insignificant, so they should price higher than otherwise?
Have several reports from various sources today. Will try to summarize by this weekend sometime.
Market Data 
Markets 
AI
